1. 1381PDGefitinib with or without pemetrexed in nonsquamous (NS) non-small cell lung cancer (NSCLC) with EGFR mutation (mut): Final overall survival (OS) results from a randomized phase II study. (23rd October 2018) Authors: Yang, J C-H; Cheng, Y; Murakami, H; Yang, P-C; He, J; Nakagawa, K; Kang, J H; Kim, J-H; Wnag, X; Enatsu, S; Puri, T; Orlando, M Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗